[1] Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2012, 380(9859): 2224-2260. [2] Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data[J]. Lancet, 2005, 365(9455): 217-223. [3] Izzo JL Jr, Gradman AH.Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure[J]. Med Clin North Am, 2004, 88: 1257-1271. [4] Gradman AH, Alfayoumi F.From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease[J]. Prog Cardiovasc Dis, 2006, 48: 326-341. [5] McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology. developed in collaboration with the heart failure association (HFA) of the ESC[J]. Eur J Heart Fail, 2012,14: 803-869. [6] Song K, Wang S, Huang B, et al. Plasma cardiotrophin-1 levels are associated with hypertensive heart disease: a meta-analysis[J]. J Clin Hypertens (Greenwich), 2014, 16: 686-692. [7] 中国高血压防治指南修订指南修订委员会.中国高血压防治指南(2018年修订版),中国心血管杂志, 2019, 24(1): 24-56. [8] Whelton PK, Carey RM, Aronow WS, et al. 2017ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. J Am Coll Cardiol, 2018, 71: e127-248. [9] Williams B, Mancia G, Spiering W, et al. 2018ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology(ESC) and the European Society of Hypertension(ESH)[J]. Eur Heart J, 2018, 39(33): 3021-3104. [10] 花琳琳,施念,杨永利,等.不同缺失值处理方法对随机缺失数据处理效果的比较[J].郑州大学学报(医学版), 2012, 47(3): 315-318. [11] Ojji D, Libhaber E, Lamont K, et al. Circulating biomarkers in the early detection of hypertensive heart disease: usefulness in the developing world[J]. Cardiovasc Diagn Ther, 2020, 10: 296-304. [12] 范红芬. 超声心动图与心电图联合诊断对高血压性心脏病疾病评估的应用价值[J].中华肿瘤防治杂志, 2016, 23(S1): 263-264. [13] 王未, 张龙江, 祁丽,等.心血管磁共振特征追踪技术的临床研究进展[J].临床放射学杂志, 2016, 35(8): 1273-1277. [14] Lopez B, Gonzalez A, Lasarte JJ, et al. Is plasma cardiotrophin-1 a marker of hypertensive heart disease?[J]. J Hypertens, 2005, 23: 625-632. [15] 张光彩,蒋玉敏,黄祥磊,等.高血压及高血压性心脏病患者检测血清hs-CRP和Hcy的临床意义[J].放射免疫学杂志, 2009, 22(4): 418. [16] 初志辉,贾晋卫,何金懋,等.超声心动图检查联合血清亲环素A与亲环素B 检测在高血压性心脏病诊断中的应用[J].中华高血压杂志, 2019, 27(11): 1080-1082 |